News & Updates

5-day antibiotic use viable in CAP patients with clinical stability

16 May 2025 by

Antibiotic treatment may be done for 5 days, as opposed to at least 7 days, in hospitalized patients with community-acquired pneumonia (CAP) who had achieved clinical stability by day 3 to 5, suggests a study presented at ESCMID Global 2025.

5-day antibiotic use viable in CAP patients with clinical stability

16 May 2025

Updated EPIC-HR data bolster nirmatrelvir/ritonavir role against COVID-19

16 May 2025 by

Updated data from the EPIC-HR* trial show reduced duration of COVID-19 symptoms and utilization of healthcare resources with nirmatrelvir/ritonavir (NMV/r) in high-risk, unvaccinated, nonhospitalized, symptomatic adults with COVID-19.

Updated EPIC-HR data bolster nirmatrelvir/ritonavir role against COVID-19

16 May 2025

Linaclotide improves bowel symptoms in children with functional constipation

16 May 2025 by

Treatment with linaclotide led to significantly improved symptoms of incomplete bowel evacuation and straining in paediatric patients aged 6–17 years with functional constipation, according to a phase III study presented at DDW 2025.

Linaclotide improves bowel symptoms in children with functional constipation

16 May 2025

Starting DOACs sooner after stroke may be best for AF patients

15 May 2025 by

For secondary stroke prevention in patients with atrial fibrillation (AF), the optimal timing of initiating a direct oral anticoagulant (DOAC) remains elusive, although evidence from a phase II study suggests that earlier initiation is better than later times within the first 2 weeks after stroke onset.

Starting DOACs sooner after stroke may be best for AF patients

15 May 2025

Tirzepatide eases MetS, cardiometabolic abnormalities in T2D

15 May 2025

Individuals with type 2 diabetes (T2D) may benefit from using tirzepatide, which has been shown in a recent study to improve cardiometabolic abnormalities and resolve metabolic syndrome (MetS).

Tirzepatide eases MetS, cardiometabolic abnormalities in T2D

15 May 2025

CAR T-cell therapy improves survival in non-Hodgkin lymphoma

15 May 2025

Treatment with chimeric antigen receptor T-cell therapies (CAR-TCT) results in significant improvements in overall (OS) and progression-free survival (PFS) among patients with refractory non-Hodgkin lymphoma (NHL) but shows no substantial effect on event-free survival (EFS), reports a study.

CAR T-cell therapy improves survival in non-Hodgkin lymphoma

15 May 2025

Rivaroxaban a game-changer for acute LV thrombus post-MI

15 May 2025 by

Patients who develop an acute thrombus in the left ventricle (LV) following myocardial infarction (MI) fare equally well when treated with rivaroxaban as they do with warfarin, as shown in the RIVAWAR study.

Rivaroxaban a game-changer for acute LV thrombus post-MI

15 May 2025

Up-to-date tetanus shots lessen disease severity, improve survival outcomes

15 May 2025

Complete childhood vaccinations help reduce the risk of mortality in adult patients with tetanus, according to a study.

Up-to-date tetanus shots lessen disease severity, improve survival outcomes

15 May 2025

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

15 May 2025 by

First-line treatment with tislelizumab plus chemotherapy showed better survival outcomes and response among patients with locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC), particularly those with high PD-L1 expression, compared with chemotherapy alone, according to a subgroup analysis of the phase III RATIONALE-304 trial presented at ELCC 2025.

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

15 May 2025

AML treatment efficacy varies by status, age, cytogenetic risk

14 May 2025

Some of the important treatment options for patients with acute myeloid leukaemia (AML) include chemotherapy, targeted therapy, and immunotherapy, but the efficacy of these treatments may vary depending on AML status, age, and cytogenetic risk, according to a study.

AML treatment efficacy varies by status, age, cytogenetic risk

14 May 2025

News & Updates

Filter by Specialty:

Specialty:

5-day antibiotic use viable in CAP patients with clinical stability

5-day antibiotic use viable in CAP patients with clinical stability

Updated EPIC-HR data bolster nirmatrelvir/ritonavir role against COVID-19

Updated EPIC-HR data bolster nirmatrelvir/ritonavir role against COVID-19

Linaclotide improves bowel symptoms in children with functional constipation

Linaclotide improves bowel symptoms in children with functional constipation

Starting DOACs sooner after stroke may be best for AF patients

Starting DOACs sooner after stroke may be best for AF patients

Tirzepatide eases MetS, cardiometabolic abnormalities in T2D

Tirzepatide eases MetS, cardiometabolic abnormalities in T2D

CAR T-cell therapy improves survival in non-Hodgkin lymphoma

CAR T-cell therapy improves survival in non-Hodgkin lymphoma

Rivaroxaban a game-changer for acute LV thrombus post-MI

Rivaroxaban a game-changer for acute LV thrombus post-MI

Up-to-date tetanus shots lessen disease severity, improve survival outcomes

Up-to-date tetanus shots lessen disease severity, improve survival outcomes

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

AML treatment efficacy varies by status, age, cytogenetic risk

AML treatment efficacy varies by status, age, cytogenetic risk